-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
▎The content team editor of WuXi AppTec today, Trigone Pharma announced that it has reached a strategic cooperation agreement with 4C Biomed to develop a new type of intravesical immunotherapy
.
The therapy is delivered directly to the bladder for the treatment of high-grade non-muscular invasive bladder cancer (HG-NMIBC)
.
This method involves the local delivery of 4C Biomed's potential "first-in-class" monoclonal antibody, which targets the herpes virus entry medium (HVEM, also known as TNFRSF14)
.
This therapy will use Trigone's proprietary delivery technology to increase the residence time of the drug, which has been shown to significantly improve the effectiveness of bladder targeted therapy
.
HVEM is a member of the tumor necrosis factor receptor family and was originally discovered as the entry route for herpes simplex virus (HSV)
.
It is expressed on the surface of T cells, B cells and other hematopoietic cells, as well as on endothelial and epithelial cells
.
HVEM interacts with the inhibitory receptor B on tumor-specific T cells and the T lymphocyte-associated receptor (BTLA), resulting in T cell suppression
.
Anti-4CB-1 antibody is a fully human anti-HVEM monoclonal antibody that can specifically block the HVEM-BTLA interaction, leading to immune cell activation, and subsequently enhancing cytotoxicity to cancer cells
.
▲The mechanism of action of the anti-4CB-1 antibody (picture source: 4C Biomed's official website) "We are very pleased to reach this cooperation with 4C Biomed
.
"Trigone Chief Medical Officer Dr.
Ofer Nativ said, "We believe that this unique combination will take advantage of the strengths of each technology and may develop a promising and powerful immunotherapy for bladder with limited clinical options other than cystectomy.
Cancer patients, they have significant unfulfilled needs
.
"4C Biomed CEO and scientific co-founder Dr.
Eyal Greenberg said: "Immunotherapy has become an important treatment option for many patients with bladder cancer.
We look forward to working with Trigone to promote new immunotherapy strategies for bladder perfusion
.
This new delivery method has the potential to enhance the bioavailability of our anti-HVEM antibody in the bladder, and enhance its anti-cancer efficacy, while providing clinical benefits, which will represent a major advancement in patient care
.
"Reference: [1] Trigone Pharma Announces a Strategic Collaboration with 4C Biomed to Develop a Novel Treatment for High-Grade Bladder Cancer.
Retrieved September 20, 2021, from https:// /09/20/2299879/0/en/Trigone-Pharma-Announces-a-Strategic-Collaboration-with-4C-Biomed-to-Develop-a-Novel-Treatment-for-High-Grade-Bladder-Cancer.
html Disclaimer: WuXi AppTec's content team focuses on introducing global biomedical health research progress
.
This article is for information exchange purposes only.
The views in the article do not represent WuXi AppTec's position, nor do it mean that WuXi AppTec supports or opposes the views in the article
.
This article is not a treatment recommendation either
.
If you need guidance on the treatment plan, please go to a regular hospital for treatment
.
.
The therapy is delivered directly to the bladder for the treatment of high-grade non-muscular invasive bladder cancer (HG-NMIBC)
.
This method involves the local delivery of 4C Biomed's potential "first-in-class" monoclonal antibody, which targets the herpes virus entry medium (HVEM, also known as TNFRSF14)
.
This therapy will use Trigone's proprietary delivery technology to increase the residence time of the drug, which has been shown to significantly improve the effectiveness of bladder targeted therapy
.
HVEM is a member of the tumor necrosis factor receptor family and was originally discovered as the entry route for herpes simplex virus (HSV)
.
It is expressed on the surface of T cells, B cells and other hematopoietic cells, as well as on endothelial and epithelial cells
.
HVEM interacts with the inhibitory receptor B on tumor-specific T cells and the T lymphocyte-associated receptor (BTLA), resulting in T cell suppression
.
Anti-4CB-1 antibody is a fully human anti-HVEM monoclonal antibody that can specifically block the HVEM-BTLA interaction, leading to immune cell activation, and subsequently enhancing cytotoxicity to cancer cells
.
▲The mechanism of action of the anti-4CB-1 antibody (picture source: 4C Biomed's official website) "We are very pleased to reach this cooperation with 4C Biomed
.
"Trigone Chief Medical Officer Dr.
Ofer Nativ said, "We believe that this unique combination will take advantage of the strengths of each technology and may develop a promising and powerful immunotherapy for bladder with limited clinical options other than cystectomy.
Cancer patients, they have significant unfulfilled needs
.
"4C Biomed CEO and scientific co-founder Dr.
Eyal Greenberg said: "Immunotherapy has become an important treatment option for many patients with bladder cancer.
We look forward to working with Trigone to promote new immunotherapy strategies for bladder perfusion
.
This new delivery method has the potential to enhance the bioavailability of our anti-HVEM antibody in the bladder, and enhance its anti-cancer efficacy, while providing clinical benefits, which will represent a major advancement in patient care
.
"Reference: [1] Trigone Pharma Announces a Strategic Collaboration with 4C Biomed to Develop a Novel Treatment for High-Grade Bladder Cancer.
Retrieved September 20, 2021, from https:// /09/20/2299879/0/en/Trigone-Pharma-Announces-a-Strategic-Collaboration-with-4C-Biomed-to-Develop-a-Novel-Treatment-for-High-Grade-Bladder-Cancer.
html Disclaimer: WuXi AppTec's content team focuses on introducing global biomedical health research progress
.
This article is for information exchange purposes only.
The views in the article do not represent WuXi AppTec's position, nor do it mean that WuXi AppTec supports or opposes the views in the article
.
This article is not a treatment recommendation either
.
If you need guidance on the treatment plan, please go to a regular hospital for treatment
.
